The cause of osteogenesis impractica is a genetic defect. It affects the body’s ability to produce collagen. The amount and quality of the collagen produced are decreased or absent. Children with this disorder have a 50% risk of developing it, but it can also appear in children without a family history. The symptoms of osteogenesis impractica are similar to those of other medical conditions and can be difficult to distinguish from those of other medical conditions.
Currently, the available treatment options such as physical therapy, bracing, and medication (Bisphosphonates) do not treat OI condition effectively.
Click To get Free SAMPLE PDF (Including Full TOC, List of Tables & Figures, Chart) @
According to a study published in The Indian Journal of Endocrinology and Metabolism, osteogenesis imperfecta (OI) is a common genetic connective tissue disorder. Around 90% are caused due to Type I collagen mutations. The Type I-IV mutations are autosomal dominant, whereas Type VI–XIII are autosomal recessive. On the basis of severity, these types are graded 1-5. The mainstay of OI treatment is bisphosphonate therapy. However, there is no such treatment available for osteogenesis imperfecta.
The growing demand for novel therapies for OI is projected to foster growth of the global osteogenesis imperfecta treatment market. For instance, in August 2016, the California-based biopharmaceutical company, Amgen Inc. developed denosumab, which is a phase III clinical trial product for OI treatment.
Impact of Coronavirus (Covid-19) Pandemic
Osteogenesis imperfecta (OI) treatment market is negatively affected during outbreak of COVID-19, as it is becoming difficult for researchers to conduct researches during this pandemic due to lockdown and social-distancing norms. Though OI does not affect the immune system, lung connective tissue is distorted in all types of OI. The risk of pulmonary problems and severity of symptoms is high in people with abnormal chest shape, short stature, rib or vertebral fractures, and kyphoscoliosis.
The all-inclusive version of the report will include the impact of COVID-19 and the probable changes in the future outlook of the industry, by taking into account the technological, social, political, and economical parameters.
Ask for PDF Brochure @
Key players are involved in research & development to develop advanced drugs and novel therapies in the osteogenesis imperfecta treatment market. This factor is expected to significantly drive the market growth and create enormous growth opportunities in the overall market during the forecast period.
For instance, in November 2017, Mereo BioPharma Group Plc received PRIME Designation from the Europe Medicines Agency for its BPS-804 (setrusumab). Setrusumabis a monoclonal antibody that targets sclerostin for the osteogenesis imperfecta treatment. This designation has enabled the company to receive health-technology assessment and scientific advice to accelerate the approval to quickly treat patients.
For instance, in October 2019, Recombinetics entered into a collaborative research project with Mayo Clinic. The aim of this collaboration was to advance osteogenesis imperfecta research by developing the first swine models of osteogenesis imperfecta. These models will aid preclinical researchers to better understand the etiology and progression of the disease and thereby, provide a trustworthy preclinical model to establish the safety and efficacy of novel therapies needed by the OI patients.
The lack of availablity of effective treatment for osteogenesis imperfecta is expected to restrict the market growth during the forecast period. Moreover, the dearth of trained professionals in some low- and middle-income countries is again expected to hamper the market growth.
Key players operating in the osteogenesis imperfecta treatment market include Bone Therapeutics SA, Mereo BioPharma Group plc, Celgene Corporation, Eli Lilly and Company, Cipla Inc., Amgen Inc, Sun Pharmaceutical Industries Limited, Mylan N.V., Teva Pharmaceutical Industries Ltd, Merck & Co., Inc., Jubilant Life Sciences Ltd., Aurobindo Pharma, and Genzyme Corp.
Reasons to Buy this Osteogenesis Imperfecta Treatment Market Report
➡ Save time carrying out entry-level research by identifying the size, growth, and leading players in the emerging Osteogenesis Imperfecta Treatment market
➡Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the emerging Osteogenesis Imperfecta Treatment market
➡Leading company profiles reveal details of key Osteogenesis Imperfecta Treatment market players emerging five operations and financial performance
➡Add weight to presentations and pitches by understanding the future growth prospects of the emerging Osteogenesis Imperfecta Treatment market with five year historical forecasts
➡Compares data from North America, South America, Asia Pacific Europe and Middle East Africa, alongside individual chapters on each region .
𝐁𝐮𝐲 𝐓𝐡𝐢𝐬 𝐂𝐨𝐦𝐩𝐥𝐞𝐭𝐞 𝐁𝐮𝐬𝐢𝐧𝐞𝐬𝐬 𝐑𝐞𝐩𝐨𝐫𝐭 𝐖𝐢𝐭𝐡 𝐅𝐥𝐚𝐭 𝐔𝐒𝐃 𝟐𝟎𝟎𝟎 𝐎𝐟𝐟 @
Table of Content
Chapter 1 Industry Overview
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Osteogenesis Imperfecta Treatment Market Size Analysis from 2021 to 2028
11.6 COVID-19 Outbreak: Osteogenesis Imperfecta Treatment Industry Impact
Chapter 2 Global Osteogenesis Imperfecta Treatment Competition by Types, Applications, and Top Regions and Countries
2.1 Global Osteogenesis Imperfecta Treatment (Volume and Value) by Type
2.3 Global Osteogenesis Imperfecta Treatment (Volume and Value) by Regions
Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis
Chapter 4 Global Osteogenesis Imperfecta Treatment Sales, Consumption, Export, Import by Regions
Chapter 5 North America Osteogenesis Imperfecta Treatment Market Analysis
Chapter 6 East Asia Osteogenesis Imperfecta Treatment Market Analysis
Chapter 7 Europe Osteogenesis Imperfecta Treatment Market Analysis
Chapter 8 South Asia Osteogenesis Imperfecta Treatment Market Analysis
Chapter 9 Southeast Asia Osteogenesis Imperfecta Treatment Market Analysis
Chapter 10 Middle East Osteogenesis Imperfecta Treatment Market Analysis
Chapter 11 Africa Osteogenesis Imperfecta Treatment Market Analysis
Chapter 12 Oceania Osteogenesis Imperfecta Treatment Market Analysis
Chapter 13 South America Osteogenesis Imperfecta Treatment Market Analysis
Chapter 14 Company Profiles and Key Figures in Osteogenesis Imperfecta Treatment Business
Chapter 15 Global Osteogenesis Imperfecta Treatment Market Forecast (2021-2028)
Chapter 16 Conclusions
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027